Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: A microsimulation model

Abstract

Although ADT with AA results in a gain in QALYs and crude OS compared to DC, AA therapy is not a cost-effective treatment strategy to apply uniformly to all patients. The availability of AA as a generic medication may help to close this gap. The ultimate choice should be based on patient and tumor factors.